Module 05a. Cardiovascular PET Tracers - Part a-Cardiovascular PET Tracers (Presentation)

Video Transcription

Video Summary

The video transcript discusses various cardiovascular PET tracers, including rubidium, ammonia, water, and fluoropyridaz. Rubidium and ammonia are FDA approved for clinical use, while water is used for research purposes and fluoropyridaz is currently in phase three clinical trials. Rubidium is a potassium analog and has a short half-life of around 78 seconds, making it unsuitable for exercise stress testing. It is delivered via a generator and has good image quality but lower contrast resolution due to its extraction and retention characteristics. Ammonia, on the other hand, has a longer half-life of 10 minutes, allowing for exercise stress testing. It has better image quality with higher contrast resolution and good retention characteristics, although it can cause uptake in the lungs and lateral wall defects. Water has a short half-life of 2.4 seconds and is not suitable for static images due to its low retention fraction. It is mainly used for quantitation of flow. Fluoropyridaz has a longer half-life of 109 minutes and is currently being studied in phase 3 trials. It has promising characteristics, including higher retention fraction and better image quality. However, it did not meet specified non-inferiority criteria in terms of specificity in phase 3 trials. Overall, PET tracers with higher energy, better extraction and retention fractions, and shorter positron ranges have higher image quality and accuracy for the detection of cardiovascular disease. The choice of tracer depends on the specific needs and diagnostic purposes of the patient.

Keywords

cardiovascular PET tracers

rubidium

ammonia

water

fluoropyridaz

FDA approved

clinical use

research purposes

phase three clinical trials

exercise stress testing